{"prompt": "['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', '8.9', 'Immunogenicity Assessments', '47', '8.10', 'Health Economics or Medical Resource Utilization and Health', 'Economics', '47', '9.0', 'STATISTICAL CONSIDERATIONS', '48', '9.1', 'Statistical Hypotheses', '48', '9.2', 'Sample Size Determination', '48', '9.3', 'Populations for Analyses', '48', '9.4', 'Statistical Analyses', '48', '9.4.1', 'Subject Disposition', '49', '9.4.2', 'Subject Characteristics and Medical History', '49', '9.4.3', 'Concomitant Medication', '50', '9.4.4', 'Efficacy Analyses', '50', '9.4.5', 'Safety Analyses', '51', '9.4.6', 'Immunogenicity Analyses', '52', '9.4.7', 'Pharmacokinetic/Pharmacodynamic Analyses', '53', '9.4.8', 'Exploratory Biomarker Analyses', '53', '9.4.9', 'Missing Data', '54', '9.5', 'Interim and Final Analyses', '54', '10.0', 'REFERENCES', '55', '11.0', 'APPENDICES', '57', 'Appendix 1', 'Abbreviations', '58', 'Appendix 2', 'Regulatory, Ethical, and Study Oversight Considerations', '60', 'Appendix 3', 'Clinical Laboratory Tests', '67', 'Appendix 4', 'Adverse Events: Definitions and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', '69', 'Appendix 5', 'Excluded Medications/Therapy', '73', 'Appendix 6', 'Contraceptive Guidance and Collection of Pregnancy', 'Information', '74', 'Appendix 7', 'Genetics', '78', 'Appendix 8', 'Clinical Global Impression', '79', 'Appendix 9', 'Modified Japanese Dermatological Association (JDA)', 'Severity Index', '80', 'Appendix 10', 'Psoriasis Area Severity Index Score (PASI)', '81', 'Appendix 11', 'Generalized Pustular Psoriasis Physician Global', 'Assessment Scale', '82', 'Appendix 12', 'Dermatology Life Quality Index', '83', 'Appendix 13 Summary of Changes', '85', '29 October 2019', '6']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'TABLE OF TABLES', 'Table 1', 'Study Treatment Details', '33', 'Table 2', 'PK/ADA Sample Collection and Timepoints', '46', 'Table 3', 'Analysis Sets', '48', 'Table 4', 'Study Administrative Structure', '62', 'Table 5', 'Protocol-required Safety Laboratory Assessments', '67', 'Table 6', 'List of Excluded Medications', '73', '29 October 2019', '7']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', '1.0', 'PROTOCOL SUMMARY', '1.1', 'Synopsis', 'Protocol Title: A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in', 'Subjects with Generalized Pustular Psoriasis', 'Rationale:', 'This study is designed to evaluate the efficacy and safety of multiple doses of ANB019 in subjects with', 'generalized pustular psoriasis (GPP). Generalized pustular psoriasis is a severe, debilitating, and', 'life-threatening systemic inflammatory disease (Marrakchi 2011, Benjegerdes 2016). The interleukin-36', '(IL-36) pathway, by promoting inflammatory responses, has been shown to play a key role in', 'pathogenesis of GPP.', 'In individuals with a normal L-36/interleukin-36 receptor (IL-36R) axis, the action of the IL-36', 'cytokines is counter-balanced by IL-36Ra, an IL-36 receptor antagonist. This natural antagonist reduces', 'excessive IL-36 response by blocking the binding of IL-36 agonist ligands to the IL-36R.', 'Several studies have identified IL-36RN mutations, the gene coding for IL-36Ra, in a subset of GPP', 'patients (Marrakchi 2011; Onoufriadis 2011; Sugiura 2012; Capon 2013, Navarini 2017). These mutations', 'disrupt the inhibitory function of IL-36Ra, leading to uncontrolled IL-36R activation. Other genetic', 'defects have also been associated with GPP, including mutations in the APIS3 and CARD14 genes (Mahil', '2016; Jordan 2012; Farooq 2013). Regardless of the presence of known mutations, activation of IL-36', 'pathway has been associated with sustained inflammatory response in GPP suggesting a key role of IL-36', 'in inflammatory skin diseases.', 'Currently, there is no approved and registered marketed therapy for GPP. Present treatment options are', 'limited to existing plaque psoriasis and systemic immunomodulatory therapies, which have limited', 'efficacy in GPP (Benjegerdes 2016). The investigational product, ANB019, is a monoclonal antibody', '(mAb) that specifically binds to IL-36R and antagonizes IL-36 signaling. Therefore, inhibition of IL-36', 'signaling by blocking IL-36R may provide a novel strategy to control the pathological inflammatory', 'cascade driven by the IL-36 pathway in patients with GPP. The information obtained from this study may', 'provide important insights into potential new treatment options for GPP.', '29 October 2019', '8']\n\n###\n\n", "completion": "END"}